EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Therapeutic Assessment of TrkB Agonist in a Unilateral Blast-Induced Hearing Loss Mouse Model

Sung Kyun Kim, Han-Gyu Bae iD, Jun Hee Kim iD

Audiology Research · 28.02.2026 · 16 (2) · 36

DOI: 10.3390/audiolres16020036 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Audiology Research, online erschienen am 28.02.2026. Verfasst von Sung Kyun Kim und 2 weiteren Autor:innen. Beteiligte Einrichtung: Kresge Hearing Research Institute, Department of Otolaryngology-Head and Neck Surgery, University of Michigan, Ann Arbor, MI 48109, USA. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: the Department of Defense (DoD).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background/Objectives: Blast-induced hearing loss (BIHL) is a major concern, particularly for military personnel, and is linked to impaired auditory neuron survival and synaptic plasticity. This study investigates the potential of the TrkB agonist 7,8-dihydroxyflavone (7,8-DHF) to reduce the severity of BIHL and promote recovery in a mouse model.

Methods

Eight-week-old male C57BL/6J mice were used. A custom-built, compressed air-driven system utilizing a modified paintball apparatus was employed to deliver controlled unilateral double blasts (~22 psi exposure pressure) to the left ear. The blasts were administered 30 min apart. Immediately following the second blast, mice received either 7,8-DHF (10 mg/kg) or vehicle (10% DMSO) via intraperitoneal injection. Auditory brainstem responses (ABRs) were measured in both ears at baseline (pre-blast) and at several post-exposure time points.

Results

The consecutive blast exposure induced a significant elevation in ABR thresholds, indicative of hearing loss, in both the ipsilateral (exposed) and contralateral (unexposed) ears of vehicle-treated mice. Notably, mice treated with 7,8-DHF demonstrated a marked improvement in hearing recovery compared to the vehicle group. Significant reductions in ABR thresholds were observed in the ipsilateral ear at 4 weeks post-blast (p < 0.0001) and in the contralateral ear as early as 1-week post-blast (p = 0.0236). However, the recovery was partial, with ABR thresholds plateauing after 4 weeks.

Conclusions

A controlled blast model demonstrates that systemic administration of the TrkB agonist 7,8-DHF exerts a protective effect, partially restoring auditory function after blast injury. This supports the therapeutic potential of targeting the BDNF-TrkB signaling pathway for managing BIHL.

Schlagwörter

Stichwörter der Autor:innen

blastbrain derived neurotrophic factorhearing loss

Autor:innen und Institutionen

  • Kresge Hearing Research Institute, Department of Otolaryngology-Head and Neck Surgery, University of Michigan, Ann Arbor, MI 48109, USA.

ORCID-Profile: Han-Gyu Bae, Jun Hee Kim

Förderung

  • the Department of Defense (DoD)

Zitieren

APA

Kim, S. K., Bae, H. G., & Kim, J. H. (2026). Therapeutic Assessment of TrkB Agonist in a Unilateral Blast-Induced Hearing Loss Mouse Model. Audiology Research, 16(2), 36. https://doi.org/10.3390/audiolres16020036

Vancouver

Kim SK, Bae HG, Kim JH. Therapeutic Assessment of TrkB Agonist in a Unilateral Blast-Induced Hearing Loss Mouse Model. Audiology Research. 2026;16(2):36. doi:10.3390/audiolres16020036

BibTeX
@article{Kim2026,
  author = {Kim, Sung Kyun and Bae, Han-Gyu and Kim, Jun Hee},
  title = {Therapeutic Assessment of TrkB Agonist in a Unilateral Blast-Induced Hearing Loss Mouse Model},
  journal = {Audiology Research},
  year = {2026},
  volume = {16},
  number = {2},
  pages = {36},
  doi = {10.3390/audiolres16020036}
}
Kostenlos starten →